Literature DB >> 22244987

Hepatic expression of cytochrome P450 in type 2 diabetic Goto-Kakizaki rats.

Soo Jin Oh1, Jong Min Choi, Kang Uk Yun, Jung Min Oh, Hui Chan Kwak, Jin-Gyo Oh, Kye Sook Lee, Bong-Hee Kim, Tae-Hwe Heo, Sang Kyum Kim.   

Abstract

Although hepatic expression of cytochrome P450 (CYP) changes markedly in diabetes, the role of ketone bodies in the regulation of CYP in diabetes is controversial. The present study was performed to determine the expression and activity of CYP in non-obese type II diabetic Goto-Kakizaki (GK) rats with normal levels of ketone bodies. In the present study, basal serum glucose levels increased 1.95-fold in GK rats, but acetoacetate and β-hydroxybutyrate levels were not significantly different. Hepatic expression of CYP reductase and CYP3A2 was up-regulated in the GK rats, and consequently, activities of CYP reductase and midazolam 4-hydroxylase, mainly catalyzed by CYP3A2, increased. In contrast, hepatic expression of CYP1A2 and CYP3A1 was down-regulated and the activities of 7-ethoxyresorufin-O-deethylase and 7-methoxyresorufin-O-demethylase, mainly catalyzed by CYP1A, also decreased in GK rats. Hepatic levels of microsomal protein and total CYP and hepatic expression of cytochrome b(5), CYP1B1, CYP2B1 and CYP2C11 were not significantly different between the GK rats and normal Wistar rats. Moreover, the expression and activity of CYP2E1, reported to be up-regulated in diabetes with hyperketonemia, were not significantly different between GK rats and control rats, suggesting that elevation of ketone bodies plays a critical role in the up-regulation of hepatic CYP2E1 in diabetic rats. Our results showed that the expression of hepatic CYP is regulated in an isoform-specific manner. The present results also show that the GK rat is a useful animal model for the pathophysiological study of non-obese type II diabetes with normal ketone body levels.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244987     DOI: 10.1016/j.cbi.2011.12.010

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  7 in total

1.  Comparative pharmacokinetics of four active components on normal and diabetic rats after oral administration of Gandi capsules.

Authors:  Renjie Xu; Jia Qi; Ruan-Juan Zhan; Gui-Sheng Zhou; Bin Hao; Jing Ma; Xin Wei; A-Jing Xu; Jian Zhang
Journal:  RSC Adv       Date:  2018-02-09       Impact factor: 4.036

2.  Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A-mediated drug hepatotoxicity.

Authors:  Jiali Liu; Xiaoliang Jin; Fang Zhou; Hongzhu Chen; Wenjie Wang; Yan Liu; Guangji Wang; Kun Hao; Jingwei Zhang
Journal:  Br J Pharmacol       Date:  2020-01-29       Impact factor: 8.739

3.  Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.

Authors:  Sarah Maximos; Michel Chamoun; Sophie Gravel; Jacques Turgeon; Veronique Michaud
Journal:  Pharmaceutics       Date:  2017-09-26       Impact factor: 6.321

Review 4.  Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis

Authors:  Imadeldin Elfaki; Rashid Mir; Fahad M Almutairi; Faisel M Abu Duhier
Journal:  Asian Pac J Cancer Prev       Date:  2018-08-24

5.  Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.

Authors:  Hana Malinska; Martina Hüttl; Olena Oliyarnyk; Irena Markova; Martin Poruba; Zuzana Racova; Ludmila Kazdova; Rostislav Vecera
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

Review 6.  Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.

Authors:  Yiting Yang; Xiaodong Liu
Journal:  Pharmaceutics       Date:  2020-04-11       Impact factor: 6.321

7.  Evaluating the effect of type 2 diabetes mellitus on CYP450 enzymes and P-gp activities, before and after glycemic control: A protocol for a case-control pharmacokinetic study.

Authors:  Navid Neyshaburinezhad; Mohammadreza Rouini; Nooshin Shirzad; Alireza Esteghamati; Manouchehr Nakhjavani; Soha Namazi; Yalda H Ardakani
Journal:  MethodsX       Date:  2020-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.